TY - JOUR
T1 - Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function
AU - Zheng, Tony J.
AU - Lofurno, Elizabeth R.
AU - Melrose, Alexander R.
AU - Lakshmanan, Hari Hara Sudhan
AU - Pang, Jiaqing
AU - Phillips, Kevin G.
AU - Fallon, Meghan E.
AU - Kohs, Tia C.L.
AU - Ngo, Anh T.P.
AU - Shatzel, Joseph J.
AU - Hinds, Monica T.
AU - McCarty, Owen J.T.
AU - Aslan, Joseph E.
N1 - Funding Information:
This work was supported by the Medical Research Foundation of Oregon, a Scholar Award from the American Society of Hematology (to J. E. Aslan) and the National Institutes of Health (R01HL146549 to J. E. Aslan, R01HL101972 to O. J. T. McCarty, R01HL130274 to M. T. Hinds, and R01HL144113 to M. T. Hinds and O. J. T. McCarty). E. R. Lofurno is a 2019 Oregon State University Johnson Scholar.
Publisher Copyright:
Copyright © 2021 the American Physiological Society.
PY - 2021/5
Y1 - 2021/5
N2 - Spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (BTK) play critical roles in platelet physiology, facilitating intracellular immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling downstream of platelet glycoprotein VI (GPVI) and GPIIb/IIIa receptors. Small molecule tyrosine kinase inhibitors (TKIs) targeting Syk and BTK have been developed as antineoplastic and antiinflammatory therapeutics and have also gained interest as antiplatelet agents. Here, we investigate the effects of 12 different Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177, BMS-986195, and fenebrutinib. In vitro, TKIs targeting Syk or BTK reduced platelet adhesion to collagen, dense granule secretion, and alpha granule secretion in response to the GPVI agonist crosslinked collagen-related peptide (CRP-XL). Similarly, these TKIs reduced the percentage of activated integrin αIIbβ3 on the platelet surface in response to CRP-XL, as determined by PAC-1 binding. Although all TKIs tested inhibited phospholipase Cγ2 (PLCγ2) phosphorylation following GPVI-mediated activation, other downstream signaling events proximal to phosphoinositide 3-kinase (PI3K) and PKC were differentially affected. In addition, reversible BTK inhibitors had less pronounced effects on GPIIb/IIIa-mediated platelet spreading on fibrinogen and differentially altered the organization of PI3K around microtubules during platelets spreading on fibrinogen. Select TKIs also inhibited platelet aggregate formation on collagen under physiological flow conditions. Together, our results suggest that TKIs targeting Syk or BTK inhibit central platelet functional responses but may differentially affect protein activities and organization in critical systems downstream of Syk and BTK in platelets.
AB - Spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (BTK) play critical roles in platelet physiology, facilitating intracellular immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling downstream of platelet glycoprotein VI (GPVI) and GPIIb/IIIa receptors. Small molecule tyrosine kinase inhibitors (TKIs) targeting Syk and BTK have been developed as antineoplastic and antiinflammatory therapeutics and have also gained interest as antiplatelet agents. Here, we investigate the effects of 12 different Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177, BMS-986195, and fenebrutinib. In vitro, TKIs targeting Syk or BTK reduced platelet adhesion to collagen, dense granule secretion, and alpha granule secretion in response to the GPVI agonist crosslinked collagen-related peptide (CRP-XL). Similarly, these TKIs reduced the percentage of activated integrin αIIbβ3 on the platelet surface in response to CRP-XL, as determined by PAC-1 binding. Although all TKIs tested inhibited phospholipase Cγ2 (PLCγ2) phosphorylation following GPVI-mediated activation, other downstream signaling events proximal to phosphoinositide 3-kinase (PI3K) and PKC were differentially affected. In addition, reversible BTK inhibitors had less pronounced effects on GPIIb/IIIa-mediated platelet spreading on fibrinogen and differentially altered the organization of PI3K around microtubules during platelets spreading on fibrinogen. Select TKIs also inhibited platelet aggregate formation on collagen under physiological flow conditions. Together, our results suggest that TKIs targeting Syk or BTK inhibit central platelet functional responses but may differentially affect protein activities and organization in critical systems downstream of Syk and BTK in platelets.
KW - BTK
KW - Ibrutinib
KW - Platelet
KW - Syk
KW - Tyrosine kinase
UR - http://www.scopus.com/inward/record.url?scp=85107572110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107572110&partnerID=8YFLogxK
U2 - 10.1152/AJPCELL.00296.2020
DO - 10.1152/AJPCELL.00296.2020
M3 - Article
C2 - 33689480
AN - SCOPUS:85107572110
SN - 0363-6143
VL - 320
SP - C902-C915
JO - American Journal of Physiology - Cell Physiology
JF - American Journal of Physiology - Cell Physiology
IS - 5
ER -